A significant retrospective cohort study has revealed that even mild levels of glucose intolerance during pregnancy are associated with a higher risk of obesity in children as they reach adolescence. The research, published in The Journal of Clinical Endocrinology & Metabolism, suggests that the in utero environment may play a more critical role in long-term...
As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of...
The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system...
A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular...
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause. Menopause can accelerate age-related weight gain and increase the likelihood of...
People with obesity and high blood pressure may face a higher risk of dementia, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Dementia is a growing global public health challenge, with no cure currently available. People with dementia experience a severe decline in mental abilities, like memory, thinking and reasoning. The most common forms of dementia are Alzheimer’s disease, vascular dementia and mixed dementia. Dementia is a progressive...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led...
As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of...
People with obesity and high blood pressure may face a higher risk of dementia, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Dementia is a growing global public health challenge, with no cure currently available. People with dementia experience a severe decline in mental abilities, like memory, thinking and reasoning. The most common forms of dementia are Alzheimer’s disease, vascular dementia and mixed dementia. Dementia is a progressive...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
